<DOC>
	<DOC>NCT00669617</DOC>
	<brief_summary>This study will evaluate the onset of action of indacaterol (150 and 300 µg) as compared to placebo, salbutamol 200 µg and salmeterol/fluticasone 50/500 µg</brief_summary>
	<brief_title>Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Male and female adults aged ≥40 years, who have signed an Informed Consent Form prior to initiation of any studyrelated procedure Patients with a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) (moderatetosevere as classified by the GOLD Guidelines, 2006) and: Smoking history of at least 20 pack years Postbronchodilator Forced Expiratory Volume in 1 Second (FEV1) &lt;80% and ≥30% of the predicted normal value. Postbronchodilator FEV1/Forced Vital Capacity (FVC) &lt; 70%, where FVC is forced vital capacity ('Post' refers to 1530 minutes after inhalation of 400 μg of salbutamol at Visit 2) Pregnant / nursing women or women of childbearing potential Long term oxygen therapy (more than 15 hours per day) on a daily basis for chronic hypoxemia Patients hospitalized for COPD exacerbation in 6 weeks prior to Visit 2 and up to Visit 3 Respiratory tract infection within 6 weeks prior to Visit 2 and up to Visit 3 Concomitant pulmonary disease, pulmonary tuberculosis (unless chest xray confirms no longer active) or clinically significant bronchiectasis Any history of asthma, including: blood eosinophil count &gt;400/mm3; onset of asthma symptoms prior to age 40 years History of long QT syndrome or whose QTc (Bazett's) measured at Visit 2 or Visit 3 is prolonged (&gt;450ms for males or &gt;470ms for females) Clinically relevant lab abnormalities / conditions such as (but not limited to) unstable ischemic heart disease, arrhythmia (excluding stable AF), uncontrolled hypertension, uncontrolled hypo and hyperthyroidism, hypokalemia, hyperadrenergic state or any condition which in the investigator's opinion might compromise patient safety or compliance, interfere with evaluation, or preclude completion of the study Uncontrolled Type I / Type II Diabetes or blood glucose outside normal or HbA1c &gt;8.0% of total hemoglobin measured at Visit 2 Any patient with lung cancer or any active cancer or a history of cancer with less than 5 years diseasefree survival time History of hypersensitivity to any of the study drugs Irregular day/night, waking/sleeping cycles e.g. shift workers Live attenuated vaccinations within 30 days prior to Visit 2 Investigational drug within 30 days prior to Visit 2 Known history of noncompliance or not able to use devices or perform spirometry Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>COPD</keyword>
	<keyword>indacaterol</keyword>
	<keyword>adults</keyword>
</DOC>